Jenburkt Pharmaceuticals Limited (NSE:JENBURPH)

Market Cap	4.23B -11.8%
Revenue (ttm)	1.69B +9.1%
Net Income	328.30M +1.2%
EPS	74.39 +1.2%
Shares Out	n/a
PE Ratio	12.88
Forward PE	n/a
Dividend	20.70 (2.19%)
Ex-Dividend Date	Aug 28, 2026

Volume	4,549
Open	961.30
Previous Close	957.20
Day's Range	940.10 - 979.80
52-Week Range	946.80 - 1,073.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 3, 2026

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations in India and internationally. The company offers therapeutic solutions, such as analgesic and antipyretics, anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants and antacids, aphrodisiac, atopic dermatitis, consumer division, cough and cold, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. It offers its products under the Allerzine, CartiSafe Forte, Crisbo, Eberjen, ECOPROT, Frendacid...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 801
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: JENBURPH

Financial Performance

In fiscal year 2026, Jenburkt Pharmaceuticals's revenue was 1.69 billion, an increase of 11.24% compared to the previous year's 1.52 billion. Earnings were 347.36 million, an increase of 8.34%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 24, 2026

Data Sources Report a data error